A retrospective evaluation of stem cell markers and tumor mutation burden as a potential risk factor for surgical recurrence (WJOG12219LTR)

A retrospective evaluation of stem cell markers and tumor mutation burden as a potential risk factor for surgical recurrence (WJOG12219LTR) - Cancer stem cell markers and tumor mutation burden in resectable non-small cell lung cancer (WJOG12219LTR)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040851

Enrollment

200

Registered

2020-06-22

Start date

2020-08-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable stage II-IIIA non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients enrolled in WJOG4107 study whose DNA and tissue samples are available.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The association of cancer stem cell markers (CD44, CD133), tumor mutation burden, PD-L1 expression on tumor cells and CD8 expression on tumor infiltrating lymphocytes, and relapse-free survival	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results